{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000165","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.434248+00:00","generated_at":"2026-06-07T00:54:58.529310+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Coherus terminates TIGIT program collaboration with Junshi Biosciences after portfolio review","bullets":["Delivered notice of termination on January 10, 2024 for the TIGIT Program (CHS-006).","Decision follows Surface Oncology acquisition and portfolio prioritization; agreement remains effective for LOQTORZI (toripalimab-tpzi).","Coherus will continue to support patients in ongoing CHS-006 studies (NCT05061628, NCT05757492).","Company believes termination is in its best interests; wind-down expected over coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000165","json":"https://secwatch.observer/filing/0001558370-24-000165.json","markdown":"https://secwatch.observer/filing/0001558370-24-000165.md","text":"https://secwatch.observer/filing/0001558370-24-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024000165/0001558370-24-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024000165/chrs-20240110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:54:58.529310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}